MediSapiens Launches OncoGenomics Explorer, First-in-Kind Cloud Computing Application for Personalized Genomics

HELSINKI, Finland and SAN FRANCISCO, September 17, 2012 /PRNewswire/ –

MediSapiens launches first-in-kind fully integrated and unified cloud computing
application that harnesses the power of Big Data and enables knowledge-based drug
discovery and repositioning for personalized genomics.

This application, called OncoGenomics Explorer, is the next stage of bioinformatics
applications for drug discovery. Unlike other cloud computing genomics applications, the
Oncogenomics Explorer allows flexible mining of all public and private multi-dimensional
biological data available and provides the user with an intuitive and concise
visualization and analysis of this vast pool of information. As the first application of
its kind, OncoGenomics Explorer also features a revolutionary new search algorithm that
allows researchers to perform complex genomics data searches using plain text search
phrases. As the result of strict data unification process, OncoGenomics Explorer users
will always get straightforward and reliable results to their queries.

The new software was launched today at the Bio-IT World’s Cloud Summit in San
Francisco by the company’s VP of Business Development, Mr. Rami Kakonen.

OncoGenomics Explorer seamlessly integrates multi-dimensional genomics (mutation,
methylation, CNV, mRNA) data from a single sample to create a comprehensive genomics tool
for scientist fighting to find the cure to cancer.

OncoGenomics Explorer is an ideal tool for the entire pharmaceutical industry. It will
significantly lower the drug discovery costs by allowing more accurate target validation
and data consolidation. It is also the first web-based omics tool to truly enable
personalized genomics because OncoGenomics Explorer allows pharmaceutical scientists to
stratify and recruit patients for clinical trials based on their personal genetic
signature. This way new therapeutic agents are more often administered to patients who are
likely to benefit from them. This, in turn, decreases drug development attrition and
overall costs, decreases the number of patients needlessly suffering from the adverse
effects of INDs, and ultimately significantly improves our odds in winning the fight
against cancer.

Medisapiens launched its first cloud computing application, the IST Online, in the
forefront of web-based gene expression data applications as early as 2005. This system has
been widely used in both academic and pharmaceutical drug discovery. The new OncoGenomics
Explorer sets a new standard for fully integrated Big Data cloud computing.

For additional information about MediSapiens, or OncoGenomics Explorer, please contact
Tommi Pisto, CEO, MediSapiens (tommi.pisto@medisapiens.com), +358-50-363-1848.

SOURCE MediSapiens Ltd.